Latest Earnings Results: Q2 '26
Estimated EPS
$0.01
Reported EPS
-$0.18
Surprise
-1582.34%
Estimated Rev
$90.12M
Reported Rev
$91M
Surprise
+0.98%
• Reported GAAP EPS of -$0.18 down -1700.00% YoY • Reported revenue of $92.1M up 28.74% YoY • Xeris Biopharma Holdings tightened its full-year 2026 total revenue guidance to a range of $385 million to $390 million, reflecting the company's confidence in its portfolio and business trajectory.
Bullish Takeaway
Xeris Biopharma Holdings achieved strong 34% year-over-year net product revenue growth and improved gross margins to 86%, while securing a key patent extension for Keveyis to protect long-term asset value.
Bearish Takeaway
Xeris Biopharma Holdings faced a widened net loss of $31.1 million in the second quarter of 2026, primarily due to a $31 million non-cash charge and elevated selling, general and administrative expenses.
Generated by Stocktwits using AI and company-reported earnings data for Q2 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q3 '26 | $0.04 | -- | -- | N/A |
Q2 '26 | $0.01 | -$0.18 | -1582.34% | MISSED |
Q1 '26 | -$0.00 | $0.01 | 464.56% | BEAT |
Q4 '25 | $0.03 | $0.06 | 116.61% | BEAT |
Q3 '25 | $0.01 | $0.00 | -100.00% | MISSED |